Leica Biosystems Added New AI Tools for Cancer Research
Researchers can now access new digital pathology algorithms for prostate and pan-cancer analysis in the Aperio AI Store.
Updated on Sept. 25, 2026 in Cancer
Live Poll
Do you believe artificial intelligence tools in medical research will ultimately improve your future patient care?
Leica Biosystems has expanded its Aperio AI Store by adding two digital pathology product suites from Tempus. These new tools are designed specifically for research use and cover a wide range of oncology applications.
Why it matters
By consolidating AI-powered algorithms into a single software interface, this integration aims to simplify complex digital pathology workflows for researchers. The move is intended to scale the adoption of AI tools in cancer study environments.
The new offerings include the Paige PanCancer Detect tool, which identifies suspicious areas across more than 40 cancer types, and the Paige Prostate suite. These products are currently limited to research use only and are not intended for clinical or diagnostic settings.
The players
Leica Biosystems
A global leader in workflow solutions and automation for cancer diagnostics and laboratory research.
Tempus
A technology company using artificial intelligence and data to advance precision medicine in oncology.
The details
The Aperio AI Store functions by embedding third-party algorithms directly into the Aperio HALO AP image management system. This centralized workflow allows researchers to run multiple AI-powered applications within one interface, reducing the technical complexity of toggling between different software platforms. The added Paige Prostate suite features specific tools for prostate detection, grading, quantification, and perineural invasion.
Timeline
October 2025: The Aperio AI Store launched in the United States.
September 24, 2026: Leica Biosystems added the new Tempus products to the store.
October 16-18, 2026: The Pathology Visions 2026 conference will take place in San Diego.
Health Landscape
Digital pathology is currently shifting toward integrated platforms that centralize diverse diagnostic and analytical tools into a single workflow. This development follows a broader industry trend of enhancing the Aperio HALO AP software workflow to better support high-throughput oncology research.
These tools are strictly for research purposes and do not currently impact individual clinical care or diagnostic procedures. If you have questions about the pathology processes used in your own care, these are best discussed directly with your physician.
The takeaway
The integration of AI into pathology research workflows aims to improve efficiency in analyzing complex cancer data. Researchers interested in these tools should look for updates at the Pathology Visions 2026 conference.
What happens next
Leica Biosystems will showcase the newly added AI applications at the Pathology Visions 2026 conference occurring October 16-18, 2026.
Further reading
For more on the latest developments in oncology tools, visit Cancer.
Source note: This article includes information reported by News-Medical.
Live Poll
Do you believe artificial intelligence tools in medical research will ultimately improve your future patient care?
